Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. High Dividend 20 Index (AUHDIV20)
3/20/2026, 12:00:00 AM
The U.S. FDA and European Commission (EC) granted expanded approvals for Opdivo (nivolumab) for treating classical Hodgkin Lymphoma, announced on March 20, 2026.
Korean Translation
2026년 3월 20일, 미국 FDA 및 유럽위원회(EC)가 전형적 호지킨 림프종 치료를 위한 옵디보(니볼루맙)의 확대 적응증을 승인함.
Related Recent Events
Manulife Financial Corp (MFC) · Earnings Release
Manulife is scheduled to release its Q1 2026 financial results after market close, scheduled.
5/13/2026, 12:00:00 AM
Exelon Corp (EXC) · Earnings Release
Exelon's Q1 2026 earnings release is scheduled for 2026-05-07. Analysts forecast an EPS of $0.89. Earnings releases typically result in significant price movement, estimated at 5% or more, forecasted.
5/7/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
UPS Q1 2026 earnings release and conference call scheduled.
4/28/2026, 12:00:00 AM
Exelon Corp (EXC) · Other
Annual meeting of shareholders scheduled to be held via webcast on 2026-04-28. Annual meetings typically have a minor market impact of approximately 1%, scheduled.
4/28/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Estimated Medium importance due to historical price volatility during earnings announcements; Q1 2026 earnings release is scheduled.
4/23/2026, 12:00:00 AM